A novel selective PKR inhibitor restores cognitive deficits and neurodegeneration in Alzheimer's disease experimental models

Authors: Matilde Lopez-Grancha, Patrick Bernardelli, Nicolas Moindrot, Elisabeth Genet, Carine Vincent, Valerie Roudieres, Alain Krick, Jean-François Sabuco¹, David Machnik, Delphine Ibghi, Laurent Pradier, Veronique Taupin²

Affiliations:

Primary Lab of origin: Neurodegeneration Cluster, Rare and Neurologic Disease Research TA, Sanofi R&D, 1 Av Pierre Brossolette, 91385 Chilly-Mazarin, France

Neurodegeneration Cluster, Rare and Neurologic Disease Research TA (MLG, NM, EG, CV, VR, DI, LP), Integrated Drug Discovery (PB, JFS, DM), DMPK (AK), Sanofi R&D, 1 Av Pierre Brossolette, 91385 Chilly-Mazarin, France

¹ Current affiliation: Toxicology, Preclinical Safety, Global Operations France, Sanofi R&D, 371 Av Prof. Blayac, 34184 Montpellier, France, veronique.taupin@sanofi.com

² Current affiliation: Evotec ID, 1541, Av Marcel Merieux, 69280 Marcy l'Etoile, France, JeanFrancois.Sabuco@evotec.com
Running Title Page

a) Running title: New potent PKR inhibitor for Alzheimer's disease

b) Corresponding author:

Veronique Taupin, PhD
Sanofi R&D, 371 Av Prof. Blayac, 34184 Montpellier, France
Tel: + 33.4.99.77.40.60
Email: veronique.taupin@sanofi.com

c) Number of text pages: 38
Number of tables: 3 (Supplemental: 3)
Number of figures: 5 (Supplemental: 5)
Number of references: 63
Number of words in abstract: 209
Number of words in introduction: 636
Number of words in discussion: 1302
d) Non-standard abbreviations:
AβO: oligomers of amyloid-beta 42
eIF2α: eukaryotic initiation factor 2α
KI: knock-in

MWM: Morris Water Maze

ORT: object recognition test

RI: recognition index

e) Recommended section: Drug discovery and translational medicine
Abstract

In Alzheimer’s disease (AD), the double-strand RNA-dependent kinase PKR/EIF2AK2 is activated in brain with increased phosphorylation of its substrate eukaryotic initiation factor 2α (eIF2α). AD risk-promoting factors, such as ApoE4 allele or the accumulation of neurotoxic amyloid-beta oligomers (AβO), have been associated with activation of PKR-dependent signalling. Here, we report the discovery of a novel potent and selective PKR inhibitor (SAR439883) and demonstrate its neuroprotective pharmacological activity in AD experimental models. In ApoE4 human replacement male mice, one-week oral treatment with SAR439883 rescued short-term memory impairment in the spatial object recognition test and dose-dependently reduced learning and memory deficits in the Barnes maze test. Moreover, in AβO-injected male mice, a two-week administration of SAR439883 in diet dose-dependently ameliorated the AβO-induced cognitive impairment in both Y-maze and Morris Water Maze, prevented loss of synaptic proteins and reduced levels of the pro-inflammatory cytokine IL-1β. In both mouse models, these effects were associated with a dose-dependent inhibition of brain PKR activity as measured by both PKR occupancy and partial lowering of peIF2α levels. Our results provide evidence that selective pharmacological inhibition of PKR by a small selective molecule can rescue memory deficits and prevent neurodegeneration in animal models of AD-like pathology suggesting that inhibition of PKR is a potential therapeutic approach for AD.
Significance Statement

We report the identification of a new small molecule potent and selective PKR inhibitor that can prevent cognitive deficits and neurodegeneration in Alzheimer’s disease (AD) experimental models including a mouse model expressing the most prevalent AD genetic risk factor ApoE4. With high potency and selectivity, this PKR inhibitor represents a unique tool for investigating the physiological role of PKR and a starting point for developing new drug candidates for AD.
Introduction

The double-strand RNA-dependent kinase PKR (EIF2AK2) is one of the four kinases phosphorylating the alpha subunit of eukaryotic initiation factor (eIF2α), thereby controlling protein translation, in a global response known as the integrated stress response. The phosphorylation of eIF2α at Ser51 is tightly regulated by these four kinases leading to inhibition of general protein translation while favoring translation of a limited subset of mRNAs including the transcription factor ATF4 (Lu et al. 2004, Vattem and Wek 2004).

PKR is activated in neurodegenerative diseases including Alzheimer’s disease (AD) as observed with accumulation of phosphorylated PKR (pPKR), its activated form, in degenerating neurons of human AD cortex and hippocampus compared to age-matched controls (Chang et al., 2002a; Peel et al., 2003; Onuki et al., 2004; Page et al., 2006; Paquet et al., 2012). Furthermore, pPKR is co-localized with phosphorylated eIF2α (peIF2α) in AD brain and in cultured neurons, Aβ oligomers (AβO) increase levels of peIF2α (Mamada et al., 2015; Chang et al., 2002b, Morel et al., 2009). In addition, levels of pPKR are increased in CSF and in peripheral blood cells of AD patients compared to healthy controls (Paccalin et al., 2006; Mouton-Liger et al., 2012; Hugon et al., 2017). pPKR has therefore been proposed as potential biomarker for AD with high pPKR levels correlating with phosphorylated Tau as well as predicting faster cognitive decline in newly diagnosed AD patients (Dumurgier et al., 2013; Paquet, 2015).

ApoE4 allele, the highest genetic risk factor to develop AD (Kim et al., 2009) has also been associated with PKR activation in human PBMC (Paccalin et al., 2006; Badia et al., 2013). PKR expression is increased in lymphocytes from young ApoE4 carriers and associated with subjective cognitive impairment (Badia et al., 2013). Consistent with these human data, humanized knock-in (KI) ApoE4 mice, have increased pelF2α levels in hippocampus and cortex associated with cognitive deficits compared to control ApoE3-KI mice (Segev et al., 2013).

PKR/eIF2α pathway is involved in both memory formation/encoding and in response to neuronal and inflammatory stress with ATF4 being critical for memory regulation (Costa-
Mattioli et al., 2007, 2009; Chen et al., 2003, Buffington et al., 2014). In human ApoE4 carriers, ATF4 is overexpressed in post-mortem brains (Baleriola et al., 2014; Segev et al., 2015). Conversely, enhanced long-term memory storage is observed in PKR-KO mice (Zhu et al., 2011) and in eIF2α-S51A mutant mice (Costa-Mattioli, 2007). PKR-KO mice were also shown to be resistant to intracerebroventricular (i.c.v) injection of AβO. AβO-induced eIF2α inhibition and amnesic effect (Lourenco et al., 2013). In double mutant 5xFAD/PKR-KO transgenic mice, spatial memory, synaptic alteration and brain inflammation were ameliorated compared to 5xFAD mice (Tible et al., 2019). Pharmacological inhibition or genetic inactivation of another eIF2α kinase, PERK, was shown to improve cognitive functions (Zhu et al., 2016) but PERK-KO mice develop pancreatic dysfunction that might represent serious liability for PERK inhibitors (Harding et al., 2001). Pharmacological inhibition of PKR with the small molecule C16 was also shown to enhance cognitive performance in wild type mice (Ingrand 2007; Stern 2013; Zhu 2011) and to reverses deficits in ApoE4-Ki (Segev et al., 2015) but C16 lacks potency and selectivity versus other eIF2AKs and other kinases (Chen et al., 2008). Our first-generation PKR inhibitor was previously demonstrated to provide neuroprotection in a short-term model of thiamine deficiency (Mouton-Liger et al., 2015).

We now report on a novel isoindolinone SAR439883 with improved selectivity as well as drug-like properties and demonstrate its protective/restorative effects on cognitive deficits and on synaptic loss in two AD-related animal models. SAR439883 is a potent and orally bioavailable PKR inhibitor highly selective versus other eIF2AKs and kinases. Oral administration of SAR439883 restores cognitive function in ApoE4-KI mice and protects from cognitive deficits and neurodegeneration markers in AβO i.c.v. injected mice. Our results suggest that PKR selective inhibition represents a potential therapeutic treatment for AD.
MATERIALS AND METHODS

Synthesis of SAR439883

SAR439883 synthetized by the medicinal chemistry department of Sanofi R&D following medicinal chemistry optimization from an isoindolinone chemical series (see structure in Fig. 1A and chemical synthesis in Supplementary information provided on-line). SAR439883 was tested through a high-throughput screening based on a biochemical assay measuring the inhibitory effect of compound on human PKR-mediated phosphorylation of its substrate eIF2α.

Biochemical assay for kinase activity

HTRF technology (Homogeneous Time Resolved Fluorescence, CisBio) was used to determine compound activity on PKR.

First, PKR or PERK or GCN2, his-tagged eIF2α (Sanofi) as substrate, ds polyIC and ATP (Sigma) as co-substrates, and MgCl₂ (Sigma) are mixed for allowing phosphorylation of eIF2α. Then, the reaction is stopped by addition of the HTRF reagents (Cisbio) diluted in HTRF buffer containing EDTA. The phosphorylated form of eIF2α is titrated by the HTRF reagents. The anti his-XL binds to the his-tag of eIF2α. The antiphospho-eIF2α-cryptate binds to peIF2α. A signal at 665 nm is generated by energy transfer from the cryptate (emission at 620 nm following laser excitation) to the XL when the two fluorophores are held in proximity. The signal at 665 nm is thus proportional to the quantity of peIF2α produced during the enzymatic reaction. Signals detected by HTRF are the fluorescence intensity at both 665 nm and 620 nm. The HTRF signal corresponds to the ratio em665 nm/em620 nm. Background signal corresponds to the ratio from control samples in which the enzyme activity is fully inhibited by an excess of EDTA or is absent. Total signal corresponds to the ratio from control samples in which enzyme is incubated with eIF2α substrate and co-substrates (ATP, ds poly IC) in the absence of inhibitor compound.

Activity on Cdk9 was measured by binding (IMAP technology, Molecular Devices) revealed by fluorescent polarization.
For PKR compound, the concentration-inhibition curve and IC50 value (concentration giving 50% inhibition of enzymatic activity) are determined by non-linear regression analysis by using Speed V2.0 software (developed by Sanofi).

**Cellular assay for PKR**

The assay for PKR activity is based on the use of an inducible HEK-293-FlpIn-TRex cell line expressing either human or murine PKR. Cells are plated in 96-well plates (Greiner, μclear Poly-D-lysine) at the density of 10 000cells/well in DMEM (Gibco Invitrogen) +10% FCS (Gibco Invitrogen) and incubated at 5% CO2, 37°C. After doxycycline induction (50mg/ml, 16 h), the compound was added and incubated for 4 h with the cells that overexpress the human recombinant PKR. At the end of the incubation, the cells were fixed with formaldehyde 4% and permeabilized with PBS/0.2% Triton X-100 for immunostaining with both rabbit anti-peIF2α (Biosource) and goat anti-eIF2α (Santacruz) antibodies. PKR activity was determined by direct measurement of the phosphorylation of the native substrate eIF2α. PeIF2α level was determined by image analysis with InCell Analyzer 2200 (GE Healthcare). The intensity of the fluorescence signal at Ex480nm/Em535 is proportional to the quantity of peIF2α in cells. The intensity of the signal at Ex595/Em620 is proportional to the quantity of total eIF2α. Cell number was measured by counting the nuclei after DAPI staining. The maximal response corresponds to the percentage of cells in the wells where the recombinant PKR is maximally induced with doxycycline and without compound.

**Cellular assay for PERK: activity on phospho-PERK (pPERK)** was evaluated by measuring the autophosphorylation of PERK in A549 cell line in which pPERK expression was induced by treatment with thapsigargin.

**Cellular assay for GCN2: activity on phospho-GCN2 (pGCN2)** was evaluated by measuring the autophosphorylation of GCN2 in A549 cell line in which pGCN2 expression was induced by treatment with L-tryptophanol.
For the tested compound, the concentration-inhibition curve and IC$_{50}$ value (concentration giving 50% inhibition of enzymatic activity) were determined by non-linear regression analysis by using Speed V2.0 software (developed by Sanofi).

**Primary neuronal cultures**

Primary neuronal cultures were prepared from brain of 16-day-old mouse (OF1, Charles River Laboratories, France) embryos by dissecting and then dissociating cerebral cortices. Cells were plated in DMEM supplemented with N2 and B27 at a cell density of 4x10^5 cells/ml in poly-D-lysine-coated wells of 96-well culture microplate. After 6 days in vitro, neurons were incubated with AβO42 (5 µM) for 48 h. Cell treatment with drug-free medium but supplemented with the corresponding DMSO concentration (i.e., 0.1%, same as for AβO treatment) was run in parallel to test substance.

Quantification of caspase 3/7 enzymatic activity

Following experimental treatment, caspase-Glo 3/7 Assay kit solution (Promega Corporation USA, G7790) were mixed to each well and then incubated for 4 hours at room temperature. After incubation, the fluorescence of each sample was quantified using a Spectramax Gemini plate reader. The measurement of fluorescence intensity is proportional to caspase 3/7 enzymatic activity.

Quantification of peIF2α levels in primary neuronal cultures

Phosphorylated elf2α levels were determined by Western blot analysis of the ratio between peIF2α and total elf2α with the following antibodies: anti-phosphoSer51 elf2α antibody (3398S, D9G8) and anti-total elf2α antibody (9722S) from Cell Signaling Technology. Briefly, aliquots of cell extracts (20 µg of protein) were separated by 4–12% gradients sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene fluoride membranes (NP0336, InvitroGen). The membranes were probed with the following antibodies: rabbit anti-elf2α and rabbit anti-peIF2α from Cell Signaling; Horseradish peroxidase-conjugated rabbit or mouse secondary antibodies were used (Promega) and after extensive washing, the immunoreactive bands were detected by
enhanced chemiluminescence (ECL Select Amersham RPN2235). Image acquisition and analysis was performed with the Amersham imager S600 and the Multi Gauge software.

Animals

Experiments were performed in our AAALAC-accredited facility or at SynAging (Contract Research Organisation, France) in full compliance with standards for the care and use of laboratory animals, according to French and European Community (Directive 2010/63/EU) legislation. All procedures were approved by the local Animal Ethic Committees and the French Ministry for Research. All animal experiments were designed with a commitment to refinement, reduction, and replacement, minimizing the number of mice and suffering via emphasis on human end points, while using biostatistical advice for optimization of mouse number.

In order to reduce the variability introduced by sex factors such as the hormonal fluctuation that occurs during the estrous cycle (Meziane et al 2007) and based on cognitive and metabolic differences between male and female ApoE3 and ApoE4-KI mice obtained in our labs (data not shown) only male mice were used in these studies.

Animals (housed 4 to 5 per cage) were kept in a pathogen-free facility at a constant temperature of 22±2°C and humidity (50±10%) on a 12 h light/dark cycle (lights on at 7 am) with ad libitum access to food and water except during the tests. All tests were conducted during the light phase at roughly the same time each day to minimize variability in performance due to time of day (between 9 am and 4 pm) except otherwise specified. For the behavioral tests, the mice were brought to the experimental room for at least 30 min acclimation prior to testing. The animals were randomized to the treatment groups according to their body weight, the timing of test sessions and the different enclosures used in the spatial recognition test. For each experiment, the mice were assigned identification numbers so that the experimenters were blinded to the treatment conditions (genotype, treatment, AβO or Vehicle i.c.v. stereotaxic injection) as well as during cognitive testing and scoring.

15 homozygous human ApoE3 and 79 male homozygous human ApoE4 targeted replacement mice (catalogue numbers 001548 and 001549, Taconic Farm) were used for
evaluating the effect of our PKR inhibitor on short and long-term memory. ApoE4 human targeted replacement mice (ApoE4-KI) express the human ApoE4 isoform under the control of endogenous murine ApoE regulatory sequences (Sullivan et al. 1997) while mouse ApoE has been deleted. C57B6/J mice obtained from Charles River were also used. For the Barnes maze test, PKR inhibitor SAR439883 (base form) was given BID by gavage at 10 and 30 mg/kg of body weight in 0.6% methylcellulose/0.5% Tween-80 for seven days (first administration in the mornings 1 h before the training and the second one 6 h later). On day 8, mice received the last administration 1 h before the probe test and were sacrificed immediately after. For spatial object recognition, 5.5-month-old mice were treated for seven days with vehicle or SAR439883 incorporated in the diet (Ssniff Spezialdiäten GmbH) at two concentrations (0.1% and 0.3%). Considering the exposure in the plasma after a single oral administration (data not shown), 0.1% SAR439883 in the diet was calculated to be bioequivalent to a 10 mg/kg single oral dose. Testing occurred on day 7.

**AβO i.c.v. injection model**

Amyloid-β1-42 (Aβ42) was obtained from Bachem (H1368, batch number 1052301). The stable Aβ42 oligomers were prepared according to SynAging protocol (Garcia et al., 2010). The oligomeric preparation contains a mixture of stable trimers and tetramers of Aβ42 as well as monomeric forms of the peptides. Oligomer preparation was previously characterized in terms of oligomer composition and in vitro neurotoxicity by SynAging and called as AβO. Global experimental design is illustrated in Fig. 4A. Briefly, 73 C57B6/J male mice (3-month-old) mice were fed with the diet, either control diet (vehicle Ssniff Spezialdiäten GmbH) or diet containing the PKR inhibitor at 3 different concentrations (0.03%, 0.1%, 0.3%), 3 days before the induction of the disease. At Day 0, mice received, under anaesthesia, a single unilateral i.c.v. injection of vehicle or AβO (50 pmol/1 µl) into the right lateral ventricle. Four days after disease induction, spatial working memory was assessed using the Y-maze test. From days +3 to days +14, learning capacities and long-term memory were investigated in the MWM assay. Animals were sacrificed at day +15 and tissues were prepared for further
ex-vivo analyses. During the entire protocol, animals were weighted every other day, from
day -10 to day +15.

**Behavioral tests**

**Y-maze and Morris Water Maze**

Immediate spatial working memory performance was assessed by recording spontaneous
alternation behavior in a Y-maze. Spontaneous alternation is a natural tendency of the
animals of numerous species including rodents to alternate their response when facing
identical and repeated choices. Its rating, in a Y maze, allows the evaluation of spatial
orientation capabilities (Hughes, 2004). Animal performances in mazes are related to the
integrity of hippocampus and spatial memory function (Means et al., 1971, Roberts et al.,
1962). The maze is made of opaque Plexiglas and each of the three arms is 40 cm long, 16
cm high, 9 cm wide and positioned at equal angles. The apparatus was placed in a
homogeneously lit test room to obtain 15 lux in all arms as well as in the central zone. Mice
are placed in the middle of one arm and are allowed to explore the maze freely during 5 min
sessions. The series of arm entries are video recorded (Smart v3.0 software, Bioseb). An
arm entry is considered complete when the hind paws of the mouse are completely placed in
the arm. Alternation is defined as successive entries into the 3 arms on overlapping triplet
sets. The percentage alternation is calculated as the ratio of actual (total alternations) to
possible alternations (defined as the number of arm entries minus two), multiplied by 100.
Locomotor activity was also recorded and evaluated by monitoring average speed and total
distance. Mice were discarded if they do not perform the minimum of twelve arm entries or if
they exhibit aberrant behaviors (e.g., mice follow the wall or presenting anxious behaviors).
Spatial learning capabilities and long-term memory were further investigated using the MWM
as described previously (Garcia et al., 2010). The experimental apparatus consists of a
circular white opaque plastic water tank (diameter, 90 cm; height, 50 cm) containing water
(21°C) to a depth of 25 cm. A white artificial colorant (Lytron) is spread over the water
surface to camouflage the escape platform (5 cm x 5 cm) made of white plastic and covered
with a wire mesh to ensure a firm grip. The pool was placed in a test room homogeneously lit
at 100 lux. The swimming paths, swimming distance, swimming speed and thigmotaxis were recorded using a video tracking system (Smart v3.0 software, Bioseb.) The MWM assay consists of 3 different steps described as followed: **Habituation (visible platform, no visual cues)** - Navigation to a visible platform was carried out before place-navigation to evaluate visual and motor abilities of mice. Mice were submitted to 4 trials (two trials in the morning and two trials in the afternoon) of 60 s each per day, during 2 consecutive days, with an inter-trial interval of at least 1 h. Once mice have found the platform, they were left alone on the platform for an additional time of 30 s. There were no additional maze cues in the room. The platform position and starting points were randomly distributed over all 4 quadrants of the pool. Mice that failed to find the platform after 60 s were guided to its location and placed on it for 30 s. After removal from the pool, mice were manually dried with a terrycloth towel and placed in their home cage. Next, **memory-acquisition** (learning trials with hidden platform, visual cues) was performed during 5 consecutive days. Several prominent visual cues on the wall near the rim of the pool were added. The hidden platform was submerged 1 cm below the water surface and placed at the midpoint of one quadrant. Mice were submitted to 4 trials of 60 s per day, with an inter-trial interval of at least 1 h. The mice were allowed to swim freely for 60 s, left alone for an additional 30 s on the hidden platform and then returned to the home cage during the inter-trial interval. Start positions (set at the border between quadrants) were randomly selected for each animal. In each trial, the time required to escape onto the hidden platform was recorded. Mice failing to find the platform within 60 s were placed on the platform for 30 s before returning to their home cage. **Memory-retention test (probe trial)** was performed three days after the last training session. The platform was removed, and each animal was allowed a free 60 s swim. During the probe trial, the time spent in the target quadrant, the number of crossings over the original platform point, and the time required for the first crossing over were registered and monitored by video tracking. In habituation, the mean latency and swim speed for the second day will be calculated for each mouse. Mice with 2 standard deviations above the group mean will be excluded, as this may be indicative of motor or visual impairments. Mice
exhibiting aberrant behavior, such as cork-screw swimming or floating most of the time will be also discarded.

**Spatial Object Recognition Test (ORT)**

This test relies on rodents' natural proactivity for exploring novelty (Ennaceur et al., 1988) and was adapted for use in mice and performed as previously described (Delay-Goyet et al., 2016). Accordingly, two weeks before the start of the study, mice were housed individually in an enriched environment. On day 1 and 2, mice were allowed to become familiar with the experimental environment twice a day for 10 min. It consisted of 4 PVC enclosures (59 x 59 x 30 cm height) with four black walls, a white floor and a video camera positioned 160 cm above the bench. The arenas were uniformly lit (30 lux). On day 3, mice were placed in the test enclosure in the presence of two identical objects placed in diagonal. Time spent exploring each object during the 10 min was recorded (exploration was defined as the animal having its head within 2 cm of the object while looking at, sniffing, or touching it). After a forgetting interval of 1 h, mice were placed back in the enclosure (recall session) for 10 min with one of the objects (A) in the same location as before (familiar), and the other object (B) in a novel location. Ambient cues in the room served as place references. Time spent exploring the familiar and novel location (in seconds) was recorded. A recognition index was calculated as follows: 100 x Time for object B / (Time for object A + Time for Object B) for the ten minutes of the recall phase. For a short-term forgetting delay, during the recall session, normal mice spent more time exploring the novel location of the object compared to the familiar one. That reflects a remembering of the familiar location. The different objects were counterbalanced and were used equally as old and novel objects. Objects were cleaned with 70% ethanol between phases, to eliminate odor cues. During both, training and testing mice should explore at least 2 s each object. First exploration should be done before 6 min otherwise, the mice will be excluded. N=12 was the sample size calculated to detect an absolute difference of at least 10% with 90% or 75% power when the variability is median and high, respectively.

**Barnes Test**
The Barnes maze task was employed to test spatial memory as described previously (Barnes 1979). It consisted of a white circular polyethylene platform 92 cm in diameter with 20 holes measuring 5 cm in diameter evenly spaced around the perimeter (2 cm from the edge) of an elevated (70 cm above the floor) maze. One of the holes led to a black Plexiglas escape box (5 x 5 x 11 cm) filled with sawdust. The maze was illuminated by overhead fluorescent white room lighting (400 lux) and surrounded by white walls, which contained spatial cues (posters with different figures). Mice were trained to locate the escape box hidden underneath one of 20 holes. The location of the escape hole remains constant throughout the training sessions. To familiarize mice with the maze and the existence of the escape hole, they were subjected to a pretraining session (identical to the training sessions). At the beginning of the trial to prevent orientation to the target, the mouse was placed in the middle of the maze under a start chamber (a cylinder black box, 12 cm in diameter), and a buzzer (80 dB) was turned on. After 10 s, the chamber was lifted and the mouse was gently guided by the experimenter to the escape hole, the buzzer was turned off, and the mouse remained into the box for 60 s. During the acquisition trials, the animals were allowed to freely explore the maze and used the distal cues, to localize and to enter the escape hole. Mice were given four training trials per day with a 15 min intertrial interval over 5 days. Each trial takes 3 min long or when the mouse enters the escape box, whatever it comes first. If a mouse did not enter the escape hole within 3 min, it was gently pulled by the experimenter to the escape box and allowed to stay there for 60 s. A 70% ethanol solution was used to wipe clean the platform after every trial and the escape box after each session. Seventy-two hours later mice were given a 90 s probe trial transfer test without the escape hole. During this trial all the holes are closed and there is no escape box. Trials were recorded using a camera mounted above the maze and animals’ movements were tracked and analyzed using a video tracking system (Viewpoint). Performance was assessed by latency to reach the virtual escape hole and time spent in the escape hole zone. Mice not moving during the 90 s of the probe test were excluded from the analysis. The sample size N=12 by group of
ApoE4 enables to show a difference at 72h of at least 50% for the parameter Time spent in the target quadrant with a power of 82%.

**Quantification of SAR439883 in blood and brain tissues**

At the completion of the experiments, mice were anesthetized using a mixture of 100 mg ketamine plus 10mg/kg xylazine and blood samples were collected by cardiac puncture into Sarstedt Lithium-Heparin gel tubes. After centrifugation (1500–2000g for 10 min at 4°C) plasma samples were frozen in microtubes and stored at −80°C. Then, brains were removed. Hippocampi, cortex, pons and cerebellum were collected and stored at −80°C until used for biochemical, RNA, or pharmacokinetics (PK) analyses. For the quantification of SAR439883 levels, after the addition of the precipitant solution (acetonitrile), SAR439883 was quantified in both plasma and pons/cerebellum samples by liquid chromatography-mass spectrometry/mass spectrometry.

**Preparation of hippocampal and brain cortical homogenates**

Hippocampi or brain cortices were homogenized in cold RIPA buffer (Cell Signaling, #9806) containing an anti-protease cocktail (Roche, #05056489001), 1 mM PMSF and 1 mM sodium orthovanadate, added freshly, just before use. Samples were vortexed, kept on ice for 10 min, and exposed to 3 freeze-thaw cycles (liquid nitrogen). Lysates were centrifuged at 800g for 15 min at 4°C. The supernatant was dispensed into aliquots and stored at -80°C for later analysis. Total protein content was assessed using the BCA assay. Data were recorded using a FLUOSTAR-Omega plate reader (BMG-LABTECH) and expressed as mg protein per ml.

**KiNativ™ binding selectivity assay**

Target occupancy in cell lysates (PC3 cell line) or in brain homogenates after in vivo treatment with SAR439883 was performed using KiNativ™ platform to quantitatively profile responses of our PKR inhibitor against PKR and all kinases detectable in brain extract. KiNativ™ is based on biotinylated acyl phosphates of ATP and ADP that irreversibly react with protein kinases on conserved lysine residues in the ATP-binding pocket. The ActivX
unique chemical probes combined with quantitative mass spectrometry of pulled-down proteins yield relative quantification of kinases detectable in sample. Presence of a catalytic site kinase inhibitor in a sample prevents ActivX probe binding and can be differentially quantified compared to samples without inhibitor. For each kinase detected, the occupancy by the inhibitor is reported as percentage vs sample without inhibitor as described by KiNativ™. PKR was detectable in brain samples as well as over 200 other ATP/ADP binding kinases.

**RT-PCR on mouse brain tissues**

Mouse brain cortical tissues were homogenized using Precellys. Total RNA extraction from the hippocampus was performed using the RNAeasy Tissue mini kit (QIAGEN) according to the manufacturer’s recommendations. Reverse transcription was performed using High-Capacity cDNA Reverse Transcription kit (Applied Biosystems). Real-time PCR was performed with TaqMan universal PCR master mix (Applied Biosystems) using the cDNA and gene specific TaqMan reactions (Applied Biosystems). Real-time PCRs were performed in triplicates using the thermocycler Quant Studio3 (Applied Biosystems) under the following conditions: 50°C for 2 min, 95°C for 10 min, and 40 cycles of 95°C for 15 s and 60°C for 1 min. Threshold cycle (Ct) values of the general activation transcription factor 4 (ATF4; Mm00515325_g1) were normalized to the Ct values of the mouse GAPDH (Glyceraldehyde 3 phosphate dehydrogenase) (Mm99999915g-1) and HPRT (hypoxanthine phosphoribosyl transferase) (Mm0154599m-1).

**Quantification of peIF2α levels in brain tissue samples**

peIF2α levels were analyzed by measuring the ratio between peIF2α and total eIF2α using Simple Western Assay (Sally Sue™, ProteinSimple Technology) designed to run an automated Western Blot-like workflow, and the following antibodies: anti-phosphoSer51 eIF2α antibody (3398S, D9G8) and anti-total eIF2α antibody (9722S) from Cell Signaling Technology. Target proteins were immunoprobbed and detected by chemiluminescence and automatically detected and analyzed.
Synaptic and neuroinflammation markers

AβO-injected animals were sacrificed at day 15 and brain tissues sampled for further ex-vivo analyses. Brain levels of PSD95, SNAP25, synaptophysin and IL1-β were assessed by ELISA in hippocampal lysates using commercially available kits using a FLUOSTAR-Omega plate reader (BMG-LABTECH) and according to manufacturer's recommendations (Cloud-Clone Corp.)

Statistical analysis

Everstat V6 based on SAS® 9.2 software was used for statistical analysis. Differences between control and treated groups were analyzed using one-way analysis of variance (ANOVA) on raw data followed by a Dunnett’s test (biochemical data; Y-maze) or repeated two-way ANOVA followed by a post-hoc Student test for each group (MMW). The significance level was taken to 5%. GraphPad/Prism software was used for figures. In spatial object recognition test, ApoE3-KI and ApoE4-KI vehicle groups were compared by performing a two-way Anova with factors Week and Group followed by a Dunnett’s test for treated mice. In the Barnes test, due to censored values for the parameter “latency to find the escape hole” in the acquisition phase a time-to-event analysis was performed for data obtained in the Barnes test. A Gehan test was used for comparing ApoE4-KI and C57B6/J vehicle groups. Gehan tests were adjusted for multiplicity by Bonferroni-Holm correction to compare ApoE4-KI treated mice. For the “latency to the escape hole” in probe trial test, a one-way ANOVA followed by a Dunnett’s test comparing ApoE-KI treated mice vs ApoE4-KI vehicle mice.

RESULTS

In vitro, SAR439883 is a soluble, potent and selective PKR inhibitor

SAR439883 has been developed by a medicinal chemistry optimization (see structure in Fig. 1A) starting from a chemical series discovered in a high-throughput screening using a biochemical assay to measure the inhibitory effect of compound on human PKR-mediated phosphorylation of its substrate eIF2α. In this assay, SAR439883 was demonstrated to be a
potent PKR inhibitor with an IC$_{50}$ of 30nM (Table 1). In inducible murine and human PKR expressing HEK cell lines, SAR439883 potently inhibited eIF2α phosphorylation with IC$_{50}$ of 0.69µM and 0.68µM, respectively (Fig. 1B). In biochemical assays, it displayed some activity on the other EIF2AK, GCN2 (62nM) but not PERK (1260nM) (Table 1). Otherwise SAR439883 had a particularly good kinase selectivity with only weak activity on CDK9 (IC$_{50}$ 964nM) and good selectivity in extensive panels of receptors and enzymes (304 kinases and 148 receptors/ion channels tested in Eurofins) (Table 1 and data not shown).

When measuring autophosphorylation SAR439883 was 30-fold more selective for PKR versus GCN2, i.e., IC$_{50}$ of 179nM for pPKR and 6.3µM for pGCN2 and showed greater than 500-fold selectivity versus other eiF2AKs PERK and HRI (Table 1 and data not shown). ActivX/Kinativ™ profiling (that measured occupancy of the ATP-binding site of all detectable kinases in a sample) confirmed activity and increased selectivity of SAR439883, particularly versus GCN2, both in cells and in vivo at Cmax of brain exposure (supplemental Table 1 and Table 2).

In isolated neuronal cultures, we demonstrated both an elevation of peIF2α induced by AβO and its reversion by SAR439883 at 3µM which correlates with its protective effect against AβO neurotoxicity as measured by caspase-3/7 enzymatic activity (supplemental Fig.1 and supplemental Table 3).

Oral bioavailability and brain penetration after oral gavage (30mg/kg) were documented in WT (Wild Type) mice under standard procedure (t1/2 = 2.6h, F$_{u}$ = 10%, Cmax brain = 6.6µM, brain to plasma ratio = 0.34; supplemental Fig.2 and data not shown). In vivo activity after oral administration was confirmed with inhibition of hippocampal peIF2α levels by -51% and -61% at tmax at doses of 30 and 100 mg/kg, respectively (supplemental Fig.3). For subchronic administration in diet and to determine the optimal timepoint for analysing PKR target engagement in brain, plasma and brain concentration of SAR439883 were analyzed in C57BL6/J mice (WT), at different timepoints (7pm, 8pm, 2am, 8am, 2pm) between Day 7 and Day 8 of treatment and the corresponding brain peIF2α decrease evaluated for both
0.1% and 0.3% doses (supplemental Table 2). As mice are known to feed more during the night than daytime, we focused the assessments during the night period to determine the maximum SAR439883 concentration. A dose-dependent increase in blood and brain total concentrations was observed together with stronger inhibition of brain peIF2α levels. Maximum inhibition of peIF2α (-53%) was obtained at 2am corresponding to highest brain compound exposure in WT mice.

**SAR439883 subchronic treatment normalizes PKR overactivation and cognitive deficits in ApoE4-KI mouse**

PKR has been shown to be overactivated and eIF2α phosphorylation increased in brain of ApoE4-KI compared to ApoE3-KI mice (Segev et al., 2013, 2015). We confirmed that levels of brain eIF2α phosphorylation were significantly increased in ApoE4-KI mice carrying 2 alleles of the human E4, compared to ApoE3 counterparts (i.e., +27%, p<0.0001; Fig. 2A). Likewise, the downstream marker of eIF2α pathway, ATF4 was upregulated in ApoE4 vs ApoE3-KI animals (p<0.0001, Fig. 2B).

The optimal experimental conditions i.e., a 7 day-treatment in diet (0.1 and 0.3%) with SAR439883 and sampling at 2am, were applied to ApoE4-KI mice. PKR inhibitor decreased brain peIF2α levels in a dose-dependent manner (-34% and -43%, at 0.1 and 0.3% in diet, respectively) trending to be lower than levels for ApoE3-KI control mice (Fig. 2A). Consistently, ATF4 mRNA expression was reversed by 52% and 61% following a 0.1 and 0.3% SAR439883 treatment respectively compared to vehicle in ApoE4-KI mouse (Fig. 2B).

Additional markers linked to ATF4/eIF2α downstream pathway, CHOP, EGR1, Ophn1, and GADD34 were investigated at the mRNA levels but were not significantly modulated by either the ApoE4 genotype or after PKR inhibitor treatment (data not shown).

Remarkably, the kinase profiling performed in ex vivo brain samples using the KiNativ™/ActivX technology revealed a strong and selective binding of SAR439883 compound to PKR (81% and 90% target occupancy for the doses of 0.1 and 0.3% in diet respectively, Table 2) and high selectivity among a panel of more than 200 kinases detected.
In association to the PKR engagement, the 7-day treatment with SAR439883 reversed deficits in short-term memory displayed by ApoE4-KI mice. As shown in Figure 2C, the recognition index (RI) (50.9% +/-1.8) displayed by vehicle ApoE4-KI mice was significantly lower p<0.0001 than for vehicle ApoE3-KI mice (65.7% +/-2.1), confirming the cognitive deficits associated to the E4 allele previously reported (Salomon-Zimri et al., 2014). In animals treated with the PKR inhibitor, mean RI were increased to 60.2 +/-2.4% (p=0.0114) and 61.6 +/-2.0% (p=0.0035) in the 0.1% and 0.3% SAR439883 dose groups, respectively (Fig. 2C). Both doses partially reversed the deficit. Two ApoE3-KI mice (vehicle) and one ApoE4-KI mice (vehicle) were excluded from the analysis due to a lack of exploration, as specified in the protocol.

Learning and long-term memory improvements were also documented in a separate study using the Barnes test (Fig. 3A). Here, SAR439883 (10-30 mg/kg BID per os) was administered from the beginning of the training. Figure 3B shows the latency to find the escape hole during the acquisition learning. ApoE4-KI mice show a strong deficit in learning process (p <0.0001 at days 3, 4 and 5) compared to C57B6J mice. ApoE4-KI mice deficits were partly reversed by SAR439883 treatment at 30 mg/kg (p<0.001) but not with the lower dose. Seventy-two hours after the last training trial, all the holes were closed, and animals were tested in a single 90-s probe trial to assess long-term spatial memory. ApoE4-KI mice displayed a longer latency to the escape hole (p=0.0017, Fig. 3C) and spent less time in the target hole quadrant (p=0.0049; Fig. 3D) than C57BL6/J vehicle mice. These long-term memory deficits in ApoE4-KI mice were reversed with the higher dose of SAR439883 (30 mg/kg; p=0.0406 and p=0.0004 for the latency to the escape hole and time spent in the escape hole quadrant, respectively) (Fig. 3C/D). There only was a non-statistically significant trend at the lower dose.

**SAR439883 prevents acute AβO-induced cognitive impairment**

It has been previously reported that i.c.v. injection of soluble Aβ oligomers (AβO) triggers inflammatory response and cellular stress leading to direct damage to synapses (Ferreira et al., 2011, 2015; Viola et al., 2015). AβO have been used as neurotoxins in experimental
mouse model (Balducci and Forluni, 2014), and triggered PKR kinase activation, promoting synapse and memory impairments (Paquet et al., 2012; Bomfim et al., 2012; Lourenco et al., 2013; Ma et al., 2013).

Therefore, we assessed the effect of our PKR inhibitor SAR439883 on the AβO-induced cognitive deficit, inflammation, and synapse loss. The full experimental design over 15 days is described in Fig. 4A. A group of animals receiving humanin was used as positive treatment control, as it has been shown to reverse inflammation and neurodegeneration in this model (Yuan et al., 2016). The spatial working memory was investigated using the Y-maze on day 4 post AβO injection. 15 mice were excluded from the analysis as specified in the protocol (less than 12 arm entries or abnormal behavior). The AβO-injected mice deficit in spatial working memory (16% decrease in alternation behavior, p=0.0019) compared to control mice was fully reversed by Humanin (p<0.05) or by the 0.3% SAR439883 diet (p<0.05; Fig. 4B). Total distance was also analyzed and showed no difference among all the experimental groups (p=0.1148) indicating that changes in alternation behavior were not due to generalized exploratory or locomotor effects. The wide dispersion at the two lower doses prevented from reaching statistical significance but trended for improvement.

Spatial learning and long-term memory were further explored in the MWM task (Fig. 4C/D and supplemental Fig. 4). Performance in the MWM is influenced by sensorimotor function and motivation, and these parameters were assessed using a visual cue test. Escape latency during the visual cue test was decreased from day 1 to day 2 in all the groups while the swim speed remained unchanged over the sessions. On learning phase, no significant differences were observed in escape latency between Vehicle mice and every group, globally and at each day (data not shown).

To assess spatial long-term memory, a probe trial was administered 72h after the last learning session. As expected AβO i.c.v. injection adversely affected performance in the probe test with an increased escape latency (p=0.0338) and a decreased number of Target crossings (p=0.001) compared to Vehicle animals. This memory impairment was completely prevented by humanin and by 0.3% SAR439883 for the latency parameter (p=0.0157 and...
p=0.0111 respectively, Fig. 4C), for the number of crossings over the platform, (p=0.0201 and p=0.0200 respectively, Fig. 4D) and for the time spent in target vs. opposite quadrant (p=0.0153 and p=0.0220 respectively, supplemental Fig. 4). AβO’s injection did not affect swim speed or total distance. Only mice treated with humanin or with the lower dose of SAR439883 (0.03%) displayed a reduction in both parameters. Swim speed (p=0.0286; p=0.0337) and total distance (p=0.0203; p=0.0401) for humanin and 0.03% of SAR439883-treated mice, respectively, were reduced without affecting the deficit in memory, suggesting that the effects observed on cognition did not reflect either dysfunction of locomotion, visual or poor swimming ability.

**SAR439883 prevents acute AβO-induced synapto-toxicity**

At the end of the treatment, brain analysis revealed that protein levels of the post-synaptic marker PSD95 and of the pre-synaptic markers synaptophysin and SNAP25 were all decreased in AβO-injected mice compared to vehicle mice (Fig. 5A). Hippocampal levels of PSD95 were decreased by 60% (Fig. 5A). Similarly, hippocampal levels of synaptophysin and SNAP25 were decreased by 59% and 44% respectively (Fig. 5B/C).

SAR439883 treatment dose-dependently reduced the loss of the 3 synaptic markers with maximal protection similar to the humanin positive control (Fig. 5).

Brain levels of IL1β were also shown to be elevated following AβO injection (+251%) and almost fully reversed after treatment with all tested doses of PKR inhibitor (i.e., 82%, 77% and 91% after 0.03%, 0.1% and 0.3% in diet, respectively) as well as with humanin treatment (Fig. 5D).

As expected, brain peIF2/εIF2α levels were dose-dependently decreased by SAR439883 treatment (-8%, -16% and -40% vs vehicle in 0.03%, 0.1% and 0.3% groups, respectively supplemental Fig. 5 and Table 3) while humanin control did not impact brain peIF2α levels. Of note, AβO injection group had the same levels than vehicle injected. Whole brain kinase occupancy profiling confirmed a dose-dependent and selective binding of SAR439883 to PKR (33%, 65%, 84% for 0.03, 0.1 and 0.3% respectively), while the other 200 kinases
detected were not occupied by the compound (Table 3 and data not shown). Dose dependent drug exposure in brain was further confirmed (Table 3).

It is noteworthy that, the robust PKR inhibition at the lowest tested dose (0.1% in diet) corresponded to free drug brain concentration of 0.15μM, calculated from values of both unbound fraction (Fu) in brain and brain exposure (data not shown and Table 2), consistent with SAR439883 cellular activity.
DISCUSSION

In the present study, we demonstrate that in vivo pharmacological inhibition of the dsRNA activated protein kinase PKR can decrease cognitive deficits in two relevant experimental models for AD and with synaptoprotective action. SAR439883 is an original isoindolone generated using high throughput screening and medicinal chemistry optimization. It is highly potent on both murine and human PKR, selective versus the other EIF2AKs PERK, HRI and GCN2 and versus a large panel of kinases and receptors.

Of note, SAR439883 is more potent than the non-selective C16 compound PKR inhibitor largely used in the literature (Ingrand et al., 2007; Chen et al., 2008) and more selective than our previous PKR inhibitor which was neuroprotective in a thiamine deficiency model (Mouton-Liger et al., 2015). In vivo SAR439883 is orally bioavailable, brain penetrant and exhibits a safe overall profile.

In line with data by Segev et al. (2013), we confirmed an increase in peIF2α levels (i.e., ratio peIF2α/total eIF2α) and of the ATF4 downstream marker in the hippocampus of ApoE4-KI mice. This increase was reversed by our selective PKR inhibitor SAR439883 demonstrating PKR activation in this model. In addition, SAR439883 reversed cognitive deficit in a 7-day treatment further supporting that inhibition of PKR/peIF2α pathway leads to enhanced long-term memory involving ATF4 reduction in mice as previously suggested (Costa-Mattioli et al., 2007).

Cognitive deficits in ApoE4-KI mice were characterized in the ORT, using experimental conditions close to human clinical tests (Lueptow, 2017), with a 1-hour inter-trial interval revealing a deficit in short term memory as previously reported (Segev et al, 2013). SAR439883 subchronic oral treatment restored short-term memory in ORT as well as learning and long-term memory in the Barnes test in ApoE4-KI mice expanding on findings with the less selective C16 PKR inhibitor (Segev et al 2015). Interestingly a single administration was not sufficient to restore ORT deficit, suggesting that sustained inhibition is necessary to reverse deficits downstream from peIF2α (data not shown). Testing
SAR439883 in other hippocampus-related behavioral tasks could be useful to further broaden the spectrum of cognitive functions potentially sensitive to treatment (Segev et al., 2015; Kornecook et al., 2010; Salomon-Zimri et al., 2014). SAR439883 pro-cognitive effect in humanized ApoE4-KI model was associated with highly selective, robust, and dose-dependent inhibition of brain PKR activity. SAR439883 brain to plasma ratio is consistently in the range of 0.2-0.34% indicating reasonable brain penetration (Hitchcock et al, 2006).

Occupancy of PKR ATP binding site (using KiNativ technology) was almost complete (90%) demonstrating that PKR was engaged in most cell types in the brain (PKR is largely distributed across brain cell types: endothelial cells and neurons) at the high dose and leading to a 43% inhibition of peIF2α levels. The partial inhibition of peIF2α is consistent with the presence in brain of PERK and GCN2, two other EIF2AKs likely responsible for the residual eIF2α phosphorylation. PERK has been reported to be the major kinase to determine levels of eIF2α phosphorylation in brain (Ounallah-Saad et al., 2014; Gal-Ben-Ari et al., 2019) but, at least in WT and in ApoE4-KI mice, PKR appears to be equally important, accounting for almost half of brain p-eIF2α levels. We could not generate any reliable data on the levels of phosphorylated PKR due to the mediocre quality of the anti-pPKR antibodies when used with mouse brain tissues.

Remarkably, the ex-vivo kinase profiling from brain samples confirmed the potency and selectivity of SAR439883 for PKR among a panel of more than 200 native kinases detected in brain extract. SAR439883 showed minimal interaction with the two EIF2AK GCN2 and PERK, further confirming its in vitro and in cell high selectivity profile.

Elevation of phosphorylated eIF2α may also trigger pro-apoptotic signals through induction of downstream CHOP (Li et al., 2010). However, CHOP was not significantly modulated in ApoE4-KI mice nor following SAR439883 treatment (data not shown). In addition, we did not observe any modulation of the expression of GADD34 which promotes the dephosphorylation of eIF2α. The absence of modulation of the memory-related transcription factor EGR1 suggested that PKR compound could enhance memory via additional ATF4-
downstream pathways. Quite similarly, no modulation of downstream markers such as Trb3 and EBR1 as well as ATF4 is observed in the second experimental model used in this study of AβO injection (data not shown). This could be explained by the rapid and transitory kinetic of this downstream response while it was analyzed here 15-day post AβO injection.

Our data further underline that partial inhibition of eIF2α via PKR inhibition is sufficient to fully reverse cognitive deficits at least in ApoE4-KI model, consistent with results in eIF2α S51A heterozygote knock-in mice (Costa-Mattioli, 2007).

The i.c.v. AβO injection model is considered as a useful complement to transgenic mouse models for the evaluation of therapeutic approaches to AD (Balducci and Forluni 2014; Ferreira et al. 2015). It recapitulates several features of the disease pathophysiology, including synaptic degeneration without the potential interference of compensation phenomenon linked to the transgenicity from the in-utero stage. Here, we used the acute i.c.v. injection of synthetic human Aβ1-42 oligomers rather than Aβ25-35 peptide that has been extensively used but miss the important conformational aspect of the full-length Aβ-derived pathological species (Murphy et al., 2010).

In accordance with previous reports (Garcia et al., 2010; Ali et al., 2015), a single injection of 50 pmol AβO produced a significant reduction in cognitive performance in Y-Maze and MWM after both 4 days (Y-maze) and 15 days (MWM). Both short-term and long-term memory deficits were prevented by SAR439883 treatment consistent with previous studies in PKR-KO mice (Lourenco et al., 2013; Zhu et al., 2011).

In addition, SAR439883 significantly prevented synaptic loss evidenced by the synapse associated proteins synaptophysin, SNAP25 and PSD95, with similar protection as the neuroprotective humanin reference peptide (Chai et al., 2014).

SAR439883 inhibited the induced-production of IL-1β in AβO-injected mice which would certainly contribute to the overall neuroprotective compound profile. Next steps could include the further documentation of the synapse protective and anti-inflammatory effects of PKR inhibition by immunohistochemistry and using other markers of microglial/astroglial activation.
that are certainly directly regulated by the eIF2α/ATF4 pathway (Couturier et al., 2012). SAR439883 synaptoprotective effect in vivo is in line with its neuroprotective properties in vitro against AβO and with our previous findings that pharmacologic PKR inhibition can protect against neuronal loss in a thiamine deficiency model characterized by oxidative stress and neuroinflammation (Mouton-Liger et al., 2015). As expected, SAR439883 could robustly decrease brain peIF2α and fully engage its target with high selectivity, quite like in the ApoE4-KI model. Previous studies have demonstrated that i.c.v. AβO induces peIF2α protein in hypothalamus and hippocampus (Lourenco et al., 2013; Clarke et al., 2015). We failed to detect any significant increase in peIF2α in the present conditions. Potential explanations could be the local increase in peIF2α remained below the detection limit of our analysis on whole hippocampal tissue and/or the transient nature of peIF2α increase which we analyzed only 2 weeks after injection. Of note, only a slight increase in peIF2α was observed right after i.c.v. AβO injection in a previous study (Hwang et al., 2017).

Interestingly, it has been recently reported that spatial memory, synaptic alteration and brain inflammation were ameliorated in double mutant 5xFAD PKR-KO mice at 9 months of age (Tible et al., 2019) and that ISR inhibition, including via PKR-deletion could improve behavioral and neurophysiological abnormalities in Down’s syndrome rodent models (Zhu et al 2019). We provide here convincing evidence that systemic treatment with a highly selective PKR inhibitor, while leading only to a partial decrease in brain peIF2α levels, prevented AβO-induced synaptic loss, neuroinflammation and subsequent cognitive deficits and importantly could reverse cognitive deficits in ApoE4-KI mice, two animal models highly relevant for AD. Downstream from p-eIF2α, the ATF4 branch of ISR was downregulated.

These data suggest that PKR could represent a promising target for therapeutic treatment in both sporadic and familial AD.
Acknowledgments: The authors thank Thierry Pillot (SynAging) for his help with the AbO-i.c.v. injection model; Martine Latta-Mahieu (Sanofi) for her help with the project; Albane Courjaud, Irene Mahfouz, Olivier Tempier, Anne Pommeret and Nadine Vaucher (Sanofi) for their help with the biochemical and cellular studies; Bernard Roisil, Joanna Tsi, Celine Prevost, Eric Brohan (Sanofi) for their help with the SAR439883 synthesis; Laurent Andrieu and his team (Sanofi) for their help with statistical analyses.

Authorship contribution:

Participated in research design: Taupin, Lopez-Grancha, Ibghi, Bernardelli, Krick, Pradier, Sabuco, Machnik

Conducted experiments: Moindrot, Genet, Vincent, Roudieres, Lopez-Grancha, Taupin

Contributed new reagents or analytic tools: Bernardelli, Sabuco, Machnik

Performed data analysis: Lopez-Grancha, Taupin, Ibghi, Bernardelli, Krick, Sabuco, Machnik

Wrote or contributed to the writing of the manuscript: Taupin, Lopez-Grancha, Bernardelli, Pradier, Ibghi
References


**Foonotes**

This study received no external funding.

Matilde Lopez-Grancha, Patrick Bernardelli, Nicolas Moindrot, Elisabeth Genet, Carine Vincent, Valerie Roudieres, Alain Krick, David Machnik, Delphine Ibghi, Laurent Pradier, Veronique Taupin are fully employed by Sanofi.

Jean-François Sabuco was fully employed by Sanofi at the time studies were conducted and is now fully employed by Evotec.

The authors declare that this manuscript is original, has not been published before and is not currently being considered for publication elsewhere.
Legends for Figures

**Fig.1** SAR439883 compound

**A.** Chemical structure of SAR439883: 6-chloro-5-[(3R,5R,6R,8R)-3,6-difluoro-1-azaspiro[4.5]decan-8-yloxy]-3,3-dimethyl-isooindolin-1-one - C19H23CIF2N2O2

**B.** Inhibition profile of phospho-eIF2α levels by SAR439883 in murine and in human PKR inducible HEK cells. Mouse or human PKR expressing HEK cells are induced overnight with doxycycline then treated with SAR439883 for 4h. Data are presented as means ± S.D. from 6 replicates per tested concentration and expressed as % peIF2α inhibition of control. Calculation of the relative IC_{50} for both human and mouse PKR determined using Speed V2.0 software.

**Fig.2** Effect of subchronic treatment with SAR439883 in ApoE4-KI mice.

SAR439883 was administered 7-day in diet. Phosphorylated eIF2 levels, ATF4 mRNA and short-term memory were evaluated by western immunoblot and following calculation of phosphorylated eIF2/total eIF2 ratio (A), using RQ-PCR (B) and spatial ORT (C), respectively. Data are presented as individual data point from each animal and as means (panel A and C) and medians (panel B) from 10 to 15 hippocampus samples per group. Sample size (based on previous experience with these assays (A and C)) and all the analysis steps have been set prior to the experiment.

(A) p values are from Dunnett's test versus vehicle groups after a one-way ANOVA, # p<0.0001 versus ApoE3 Vehicle; * p<0.0001 versus ApoE4 Vehicle. (B) p values are from Dunnett's test following a ranked delta CT and after one-way ANOVA, # p<0.0001 versus ApoE3 Vehicle; * p<0.0001 versus ApoE4 Vehicle. (C) p values are from two-way Anova on recognition index # p<0.0001 versus ApoE3 Vehicle; and Dunnett's test following a two-way ANOVA on recognition index *p= 0.0114; ** p=0.0035 versus ApoE4 Vehicle.
Fig.3 Effect of subchronic treatment of SAR439883 in learning and long-term memory.
SAR439883 was administered at 10 and 30 mg/kg BID p.o. for 8 days to ApoE4-KI mice. Spatial learning and long-term memory were assessed using the Barnes Test (A). For latency to the escape hole in the acquisition phase (B), data are presented as medians [Q1; Q3] by group and by day. *p-values are obtained from Gehan test at each day between vehicle C57B6/J and vehicle ApoE4 treated mice, ***p<0.0003, p<0.0001 and p<0.0001 for day 3, 4 and 5, respectively. #p-values obtained with Gehan tests with Bonferroni-Holm correction of ApoE4 treated mice at 30mg/kg versus ApoE4 vehicle at each day #p<0.0363, ##p<0.0015.
Probe test was performed 72h after the last training day: latency to the escape hole (C) and time in the escape hole quadrant (D). Scatter dot plots show median, [Q1; Q3], maximum and minimum values. #p-values are from student t-test ApoE4 vehicle mice versus C57BL6/J for the parameters Latency to target hole (C, ## p=0.0017) and time spent in the target zone (D, ## p=0.0049); *p-values are obtained from one-way ANOVA followed by a Dunnett's test comparing ApoE4 treated mice vs ApoE4 vehicle mice for the same both parameters (C, *p=0.0406; D, ***p=0.0004).
Sample size (N=12) have been calculated after the experiment as we did not have enough data set.

Fig.4 Effect of SAR439883 on memory impairment in AβO i.c.v. mouse.
SAR439883 was administered at 0.03, 0.1 and 0.3% in diet for 18 days to AβO i.c.v. injected C57B6/J mice. Schedule of the different tests are described in panel A.
The effect on working memory impairment was evaluated using the spontaneous alternation in the Y maze test (B). p values were obtained from either a Student test (Vehicle versus AβO; Humanin versus AβO) or a one-way ANOVA followed by a Dunnett’s test to compare compound effect at 0.03%, 0.1% and 0.3% in diet to vehicle AβO group.
The effect on spatial long-term memory was evaluated using the MWM (panels C/D). Individual data and boxplot by group present Medians, [Q1; Q3], maximum and minimum values per group and means +/- S.D. Probe test was performed 72h after the last training day: latency to target platform (C). A log-rank test was performed to compare AβO to Vehicle group and Humanin AβO to AβO group. p values are obtained from one-way ANOVA on ranks followed by multiple comparisons with Dunnett’s correction.

# p=0.0338; * p=0.0157; ** p=0.0111 and number of target crossings (D) p-value are from a Student t-test for pathology induction (AβO versus Vehicle) and for humanin effect versus AβO and from Dunnett’s test after a one-way ANOVA. # p=0.0010; * p=0.0201; ** p=0.0200.

All analysis steps and the sample size per group have been decided before we performed the experiments. Sample size was unequal for one group (N=9) at the beginning of the experiment N=13 for the rest.

**Fig.5** Effect of SAR439883 18-day diet treatment on synaptic protein loss and inflammation in AβO i.c.v. injection model.

SAR439883 was administered at 0.03, 0.1 and 0.3% in diet for 18 days to AβO - i.c.v. injected mice. At the end of the treatment period, synaptic proteins, i.e. PSD95 (A), synaptophysin (B), SNAP25 (C) and IL1β (D) were measured in the individual brain homogenates by ELISA.

Individual data and boxplot by group present Medians, [Q1; Q3], maximum and minimum values per group, and means + S.D. p values are from Dunnett’s test versus AβO after a one-way ANOVA, #p<0.0001 ***p<0.0001, **p<0.001, * p<0.05.

All analysis steps and the sample size per group have been decided before we performed the experiment. Sample size was unequal for one group (N=9) at the beginning of the experiment N=13 for the rest.
Table 1. In vitro profile of SAR439883 compound

Data are expressed as means ± S.D. from 1 (Cellular GCN2) to 5 independent experiments.

<table>
<thead>
<tr>
<th>ACTIVITY</th>
<th>KINASE</th>
<th>SAR439883 IC₅₀ (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biochemical (human)</td>
<td>PKR (pelF2α, ATP 40 µM)</td>
<td>30 ±3</td>
</tr>
<tr>
<td></td>
<td>PERK (ATP 2 µM)</td>
<td>1260 ±121</td>
</tr>
<tr>
<td></td>
<td>GCN2 (ATP 40 µM)</td>
<td>62 ±4</td>
</tr>
<tr>
<td></td>
<td>CDK9 (ATP 10 µM)</td>
<td>964 ±103</td>
</tr>
<tr>
<td>Cellular (human)</td>
<td>PKR (pPKR)</td>
<td>179 ±53</td>
</tr>
<tr>
<td></td>
<td>PKR (p-eIF2α)</td>
<td>678 ± 149</td>
</tr>
<tr>
<td></td>
<td>PERK (pPERK)</td>
<td>inactive up to 30 000</td>
</tr>
<tr>
<td></td>
<td>GCN2 (pGCN2)</td>
<td>6300</td>
</tr>
</tbody>
</table>
Table 2. Effect of a 7-day treatment with SAR439883 on PKR activation and cognition in ApoE4 mouse

Data are expressed as means ± S.E.M.

a. Δ points: delta of Recognition Index (ORT)

b. Inhibition of PKR pathway (peIF2α and ATF4 brain expression) by SAR439883

c. PKR selectivity measured in ex-vivo brain samples

d. compound concentrations measured in pons/cerebellum samples

<table>
<thead>
<tr>
<th>SAR439883 (% in diet)</th>
<th>COGNITION</th>
<th>PKR ENGAGEMENT</th>
<th>COMPOUND CONCENTRATION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ORT (Recognition index; Δ points) a</td>
<td>peIF2α inhibition (%) b</td>
<td>Brain (µM) d</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ATF4 Reversion (%) b</td>
<td>GCN2 (µM) d</td>
</tr>
<tr>
<td>0.1%</td>
<td>9.3 ±0.4 (p=0.0114)</td>
<td>34.3 ±1.8 (p&lt;0.0001)</td>
<td>81.2 ±1.4</td>
</tr>
<tr>
<td>0.3%</td>
<td>10.7 ±0.3 (p=0.0035)</td>
<td>43.4 ±2.8 (p=0.0001)</td>
<td>90.2 ±1.8</td>
</tr>
</tbody>
</table>
Table 3. Effect of an 18-day treatment with SAR439883 on PKR activation and cognition in AβO i.c.v. model

* data are from 12 to 13 brain samples (brain cortex) per group that were pooled by 3 to 4 samples.

** data are from 10 to 12 brain samples (hippocampus) per group; p values obtained with a Dunnett's test versus AβO after a one-way ANOVA.

$ data are from 12 to 13 brain samples (pons/cerebellum) per group.

<table>
<thead>
<tr>
<th>SAR439883 dose (in diet; 18 days)</th>
<th>PKR occupancy in brain (ActivX/KiNativ™) (%)</th>
<th>peIF2α inhibition in brain (% AβO group)</th>
<th>Brain exposure (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.03 %</td>
<td>32.7 ±5.3 *</td>
<td>8.0 ±0.3</td>
<td>0.11 ±0.03$</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>0.1 %</td>
<td>65.4 ±7.7 *</td>
<td>15.7 ±0.5</td>
<td>0.34 ±0.13$</td>
</tr>
<tr>
<td></td>
<td></td>
<td>p=0.0096**</td>
<td></td>
</tr>
<tr>
<td>0.3 %</td>
<td>84.2 ±3.1 *</td>
<td>40.0 ±1.4</td>
<td>1.06 ±0.34$</td>
</tr>
<tr>
<td></td>
<td></td>
<td>p&lt;0.0001**</td>
<td></td>
</tr>
</tbody>
</table>
Figure 1

A. Chiral

B. 

![Graph showing pE2 inhibition (%) vs. concentration (μM) for human and mouse PKR IC50 values.](image-url)
Figure 2.

A. 

B. 

ATF4 mRNA expression (RQ)
c.

![Bar chart showing recognition index (%) with different treatment conditions: Vehicle, 0.1%, and 0.3% SAR439883 for ApoE3-KI and ApoE4-KI.

Legend: • Vehicle, ▲ 0.1%, ▼ 0.3%

Significance: # p < 0.05, * p < 0.01, ** p < 0.001]
Figure 3.

A. Acquisition phase (open holes) and Probe Trial (close holes).

B. Graph showing latency to escape hole over days with different treatments.

Legend:
- C57Bl/6J VEH
- ApoE4-KI VEH
- ApoE4-KI SAR439883-10 mg/Kg
- ApoE4-KI SAR439883-30 mg/Kg

Significance levels:
- # p < 0.05
- ** p < 0.001
- ### p < 0.0001
Figure 4.

A

Regular diet
-10
-3
0
+3
+4
+7
+11
+14
+15

SAR439883 in diet

DAYS

(+) AβO
ICV

MWM
(habituation)

Y-maze

MWM
(learning)

MWM
(probe)

Brain collection for ex-vivo analysis

B

Spontaneous alternation (%)

Vehicle
Vehicle
Humanin
0.03%
0.01%
0.3%
SAR439883

Vehicle
AβO

* **

#
Figure 5.

A.

B.
A novel selective PKR inhibitor restores cognitive deficits and neurodegeneration in Alzheimer's disease experimental models

Authors: Matilde Lopez-Grancha, Patrick Bernardelli, Nicolas Moindrot, Elisabeth Genet, Carine Vincent, Valerie Roudieres, Alain Krick, Jean-François Sabuco, David Machnik, Delphine Ibghi, Laurent Pradier, Veronique Taupin

Supplemental Fig. 1
SAR439883 effect on Aβ42 oligomer (AβO)-induced neurotoxicity in vitro.

Effect of SAR439883 (3μM) on cell viability was measured by caspase-3/7 enzymatic activity induced by AβO (5μM) in mouse primary neuronal cultures. Humanin (1μM) was used as reference neuroprotective compound. Data are expressed as means ± S.D. from 4 biological replicates. P values are from Dunnett's test after a one-way ANOVA. # p <0.0001 versus Control; *p <0.0001 versus Control (+) AβO.
Supplemental Fig. 2
Pharmacokinetic profile of SAR439883 in plasma and brain of WT mouse.
Pharmacokinetic parameters were determined following a single intravenous (3 mg/kg) or oral (30 mg/kg) administration of SAR439883 to male C57Bl6 mice (n=3).
Formulations used: iv Glycofurol/PS80/G5 (10%/5%/85%); po MC/Tween (0.6%/0.5%) pH=6.

<table>
<thead>
<tr>
<th>Route</th>
<th>Dose (mg/kg)</th>
<th>Matrix</th>
<th>C₀ or Cmax (ng/mL or µg)</th>
<th>tmax (h)</th>
<th>AUClast (ng h/mL or µg)</th>
<th>t1/2 (h)</th>
<th>AUC (ng h/mL or µg)</th>
<th>CL (L/h/kg)</th>
<th>Vss (L)</th>
<th>t1/2 (h)</th>
<th>Brain/Plasma AUC ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>i.v.</td>
<td>3</td>
<td>Plasma</td>
<td>2150</td>
<td>-</td>
<td>1560</td>
<td>8</td>
<td>1610</td>
<td>1.86</td>
<td>3.23</td>
<td>1.68</td>
<td>-</td>
</tr>
<tr>
<td>p.o.</td>
<td>30</td>
<td>Plasma</td>
<td>8130</td>
<td>1</td>
<td>24600</td>
<td>24</td>
<td>24600</td>
<td>-</td>
<td>-</td>
<td>2.35</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Brain</td>
<td>2560</td>
<td>1</td>
<td>8370</td>
<td>24</td>
<td>8380</td>
<td>-</td>
<td>-</td>
<td>2.59</td>
<td>0.340</td>
</tr>
</tbody>
</table>
Supplemental Fig. 3

Effect of SAR439883 on peIF2α levels in hippocampus of C57Bl6 mouse

SAR439883 was administered at 30 (■) and 100 (▲) mg/kg by gavage to C57Bl6 mice and peIF2α levels were measured in the hippocampus by WB and compared to vehicle group (○).

Data are presented as individual data point for each animal sample (n=8 per group). The pons/cerebellum from the same animals were used to evaluate compound exposure (mean values are indicated for each dose in the table below).
Supplemental Fig. 4
Effect of SAR439883 on memory impairment in AβO i.c.v. mouse (MWM).

SAR439883 was administered at 0.03, 0.1 and 0.3% in diet for 18 days to AβO i.c.v. injected C57B6/J mice.

Probe test was performed 72h after the last training day: time spent in the Target Quadrant (TQ) versus Opposite Quadrant (OQ). Individual data and boxplot by group present Medians, [Q1; Q3], maximum and minimum values per group. p-value are from a post hoc Student test after a repeated two-way ANOVA, * p=0.0378; ** p=0.0220; *** p=0.0153 TQ versus OQ in the same treatment group,

All analysis steps and the sample size per group have been decided before we performed the experiment. Sample size was unequal for one group (N=9) at the beginning of the experiment N=13 for the rest.
Supplemental Fig. 5

Effect of SAR439883 18-day diet treatment on peIF2α levels in AβO i.c.v. injection model

SAR439883 was administered at 0.03, 0.1 and 0.3% in diet for 18 days to AβO- i.c.v. - injected mice. At the end of the treatment period, peIF2α levels were measured in the individual brain homogenates by WB. Data are presented as individual data point for each animal sample and as means ± S.D. from 8 to 12 individual brain homogenates.

P values are from Dunnett's test versus AβO after a one-way ANOVA

**p<0.01 ***p<0.0001
Supplemental Table 1

SAR439883 selectivity profile using KiNativ™ technology (ActivX Biosciences, San Diego, CA) in in vitro cells or in vivo 2h after oral treatment in ApoE4 mice.

a. Data are from lysates of PC3 cell treated at 6 concentrations for IC$_{50}$ determination
b. Data are mean ± S.E.M. from 5 pooled brain homogenates (3 brains per pool) from ApoE4 mice

*NT: not tested

<table>
<thead>
<tr>
<th>Kinase</th>
<th>IC$_{50}$ (µM)</th>
<th>% inhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td>PKR</td>
<td>0.073</td>
<td>74.1 ± 1.8</td>
</tr>
<tr>
<td>GCN2</td>
<td>8-12</td>
<td>8.8 ± 5.2</td>
</tr>
<tr>
<td>PERK</td>
<td>8.8</td>
<td>NT*</td>
</tr>
<tr>
<td>CDC2</td>
<td>NT*</td>
<td>28.8 ± 4.8</td>
</tr>
<tr>
<td>SRPK1, SRPK2</td>
<td>&gt;30</td>
<td>28.1 ± 4.3</td>
</tr>
<tr>
<td>RSK2</td>
<td>&gt;30</td>
<td>26.4 ± 4.3</td>
</tr>
<tr>
<td>RSKL1</td>
<td>NT*</td>
<td>22.4 ± 4.7</td>
</tr>
<tr>
<td>ULK3</td>
<td>NT*</td>
<td>20.1 ± 3.3</td>
</tr>
<tr>
<td>other 111 kinases</td>
<td>&gt;30</td>
<td></td>
</tr>
<tr>
<td>other 194 kinases</td>
<td>&gt;30</td>
<td>&lt;20</td>
</tr>
</tbody>
</table>
Supplemental Table 2
Kinetics and associated pharmacodynamic response to SAR439883 treatment in diet in WT mice.
Data are means +/- S.D. from 10 individual animals for exposure data or means from 8 to 10 animals expressed as % of inhibition vs. vehicle group for peIF2α data.

<table>
<thead>
<tr>
<th>SAR439883 dose</th>
<th>readout</th>
<th>7 PM</th>
<th>8 PM</th>
<th>2 AM</th>
<th>8 AM</th>
<th>2 PM</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.1%</td>
<td>Plasma exposure (µM)</td>
<td>3.7 ± 0.8</td>
<td>6.1 ± 1.1</td>
<td>8.4 ± 2.0</td>
<td>5.8 ± 1.4</td>
<td>2.8 ± 1.1</td>
</tr>
<tr>
<td></td>
<td>Brain exposure (µM)</td>
<td>0.8 ± 0.2</td>
<td>1.4 ± 0.3</td>
<td>1.6 ± 0.3</td>
<td>1.2 ± 0.2</td>
<td>0.6 ± 0.2</td>
</tr>
<tr>
<td></td>
<td>Brain peIF2α/eIF2α decrease (%vehicle)</td>
<td>21</td>
<td>24</td>
<td>27</td>
<td>25</td>
<td>10</td>
</tr>
<tr>
<td>0.3%</td>
<td>Plasma exposure (µM)</td>
<td>6.7 ± 2.9</td>
<td>10 ± 3.6</td>
<td>16.4 ± 3.8</td>
<td>8.6 ± 2.2</td>
<td>4.3 ± 1.4</td>
</tr>
<tr>
<td></td>
<td>Brain exposure (µM)</td>
<td>1.4 ± 0.5</td>
<td>2.1 ± 0.9</td>
<td>3.2 ± 0.6</td>
<td>1.7 ± 0.4</td>
<td>0.8 ± 0.3</td>
</tr>
<tr>
<td></td>
<td>Brain peIF2α/eIF2α decrease (%vehicle)</td>
<td>47</td>
<td>40</td>
<td>53</td>
<td>27</td>
<td>22</td>
</tr>
</tbody>
</table>
Supplemental Table 3

SAR439883 effect on Aβ42 oligomers (AβO)-induced neurotoxicity in vitro: Effect on peIF2α levels.

Data are means from pooled samples from one exploratory study.

<table>
<thead>
<tr>
<th>Cell treatment</th>
<th>peIF2α levels ( % control )</th>
</tr>
</thead>
<tbody>
<tr>
<td>AβO</td>
<td>177</td>
</tr>
<tr>
<td>AβO + SAR439883 3 µM</td>
<td>97</td>
</tr>
</tbody>
</table>
Supplementary information:

Synthesis of SAR439883 compound

Reagents were purchased from commercial suppliers and were used without purification unless otherwise noted. Normal-phase column chromatography was performed on silica gel using prepacked cartridges. Proton nuclear magnetic resonance (\(^1\)H NMR) spectra were recorded on a Bruker 400MHz spectrometer. Chemical shifts for \(^1\)H NMR spectra are reported in ppm (d) relative to residue protium in the solvent (DMSO); the multiplicities are presented as follows: s = singlet, d = doublet, t = triplet, m = multiplet, coupling constants \(J\) in Hertz (Hz), integration. Mass spectra (MS) were obtained on a SQD Waters spectrometer using electrospray ionization (ESI) in positive mode. Calculated (calcd.) mass corresponds to the exact mass. Chemical names were generated using BIOVIA Draw 18.1 (Dassault Systèmes).

Step 1: \text{rac-(2R,4R)-4-benzylxyo-2-fluoro-cyclohexanone}
To a mechanically stirred solution of 4-benzyloxy cyclohexanone (500 g, 2.45 mol) and triethylamine (997 mL, 7.17 mol, 2.9 equiv.) in dichloromethane (DCM) (7 L) at -5°C under nitrogen was dropwise added a solution of trimethylsilyl trifluoromethanesulfonate (491 mL, 2.78 mol, 1.1 equiv.) in DCM (1.5 L) over 3 hours while maintaining the temperature below 0°C. The mixture was mechanically stirred for 15 minutes at 0°C and then a saturated aqueous NaHCO$_3$ solution (10 L) was added. After stirring for 5 minutes the layers were separated. The aqueous layer was extracted with DCM (1 L). The combined organic layers were washed with brine (2.5 L), dried over sodium sulfate and concentrated under reduced pressure to give the corresponding trimethylsilyl enol ether (816.7 g) as a brown oil. To a solution of the resulting intermediate (816.7 g, 2.45 mol) in acetonitrile (7.5 L) was portionwise added Selectfluor (1101 g, 3.11 mol, 1.3 eq) in 1 hour while maintaining the temperature below 25°C with an ice-bath. The mixture was stirred for 2 hours allowing the temperature to warm up to room temperature. Diethylether (10 L) was added, and the precipitate was filtered through Celite and washed with diethylether (3 L). The filtrate was concentrated under reduced pressure to give 1198 g of a crude mixture of diastereomers as a brown oil. This mixture was separated by column chromatography on silica gel eluting with a gradient of 0.05% to 5% methanol in dichloromethane. The second eluting product was collected and concentrated under reduced pressure then taken into ethyl acetate (220 mL) followed by heptane (880 mL). After stirring for 45 minutes, the product was filtered, washed with heptane (100 mL) and dried under vacuum to give 110 g (20%) of rac-(2R,4R)-4-benzyloxy-2-fluoro-cyclohexanone as a white solid. MS (EI): mass calcd. for C$_{13}$H$_{15}$FO$_2$, 222; m/z found, 222 [M+]. $^1$H NMR (400 MHz, CDCl$_3$): d 7.32-7.43 (m, 5 H), 4.90 (ddd, $J = 48.0, 12.4, 6.8$ Hz, 1 H), 4.62 (s, 2 H), 3.83-3.90 (m, 1 H), 2.80-2.83 (m, 1 H), 2.52-2.54 (m, 1 H), 2.28-2.32 (m, 2 H), 1.94-2.00 (m, 1 H), 1.75-1.79 (m, 1 H).

Step 2: rac-(1S,2S,4S)-1-allyl-N-benzyl-4-benzyloxy-2-fluoro-cyclohexanamine

To a solution of rac-(2R,4R)-4-benzyloxy-2-fluoro-cyclohexanone (25 g, 112.48 mmol) in 7N methanolic ammonia solution (170 mL, 1.19 mol, 10 equiv.) was added 2-allyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (27 mL, 143 mmol, 1.27 equiv.). The mixture was stirred for
24 hours at room temperature and then concentrated under reduced pressure. To a mixture of the crude product and potassium carbonate (47 g, 340 mmol) in dimethylformamide (DMF, 200 mL) was added benzyl bromide (27 mL, 227 mmol). The mixture was stirred at room temperature for 20 hours then poured onto water (1 L) and extracted with diisopropyl ether (1 L). The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with a gradient of 0 to 10% diisopropyl ether in heptane to give 30.9 g (79%) of rac-(1S,2S,4S)-1-allyl-N-benzyl-4-benzyloxy-2-fluoro-cyclohexanamine as a colorless oil. MS (ESI): mass calcd. for C_{23}H_{28}FNO, 353.4; m/z found, 354.3 [M+H]^+. 1H NMR (400 MHz, DMSO-d6): δ 7.21-7.36 (m, 10 H), 5.84-5.94 (m, 1 H), 5.08-5.14 (m, 2 H), 4.40-4.55 (m, 3 H), 3.63-3.74 (m, 2 H), 3.37-3.40 (m, 1 H), 2.33-2.47 (m, 2 H), 1.11-1.76 (m, 7 H).

**Step 3: rac-(5S,6S,8S)-1-benzyl-8-benzyloxy-6-fluoro-1-azaspiro[4.5]decan-3-ol**

To a vigorously stirred mixture of rac-(1S,2S,4S)-1-allyl-N-benzyl-4-benzyloxy-2-fluoro-cyclohexanamine (30.9 g, 87.4 mmol) in a 5% aqueous solution of sodium bicarbonate (900 mL) and dichloromethane (600 mL) was dropwise added a solution of iodine (31 g, 122.1 mmol, 1.4 equiv.) in dichloromethane (1200 mL) over 45 minutes. The mixture was vigorously stirred overnight. The organic layer was separated, washed with brine (200 mL) and concentrated under reduced pressure to give crude rac-(5S,6S,8S)-1-benzyl-8-benzyloxy-6-fluoro-3-iodo-1-azaspiro[4.5]decane as a deep red oil that was used directly in the next step without further purification. MS (ESI): mass calcd. for C_{23}H_{27}FNO, 479.1; m/z found, 480.1 [M+H]^+. To a solution of the resulting product (41.91 g) in acetone (730 mL) was added a solution of silver tetrafluoroborate (19 g, 96.6 mmol) in water (90 mL) over 10 minutes. The yellow suspension was stirred for 45 minutes at room temperature. The reaction mixture was then poured onto diluted aqueous Na_2CO_3 solution (700 mL) and extracted with ethyl acetate (500 mL). The whole mixture was filtered on dicalite. The organic layer was separated and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with a gradient of 0 to 5% methanol in dichloromethane to give 24.7 g (77% over 2 steps) of rac-(5S,6S,8S)-1-benzyl-8-
benzyloxy-6-fluoro-1-azaspiro[4.5]decan-3-ol as a deep orange solid. MS (ESI): mass calcd. for C_{23}H_{28}FNO_2, 369.2; m/z found, 370.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6): δ 7.06-7.38 (m, 10 H), 4.39-4.89 (m, 4H), 4.01-4.09 (m, 2 H), 3.50-3.60 (m, 2 H), 2.60-2.86 (m, 1 H), 2.26-2.37 (m, 2 H), 1.13-1.61 (m, 6 H).

Step 4: rac-(3S,5S,6S,8S)-1-benzyl-8-benzyloxy-3,6-difluoro-1-azaspiro[4.5]decan-3-ol

To a solution of rac-(5S,6S,8S)-1-benzyl-8-benzyloxy-6-fluoro-1-azaspiro[4.5]decan-3-ol (18.61 g, 50.37 mmol) in dry dichloromethane (300 mL) at -10°C under a dry argon atmosphere was dropwise added diethylaminosulfur trifluoride DAST (10.4 mL, 78.71 mmol, 1.5 equiv.). The mixture was stirred for 2 hours allowing the temperature to warm up to room temperature then poured onto saturated aqueous NaHCO_3 solution (500 mL) and dichloromethane (200 mL). The pH was slowly made basic with careful solid NaHCO_3 addition. The layers were separated and the aqueous layer extracted with dichloromethane (200 mL). The combined organic layers were dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with a gradient of 20 to 100% dichloromethane in heptane to give 3.9 g (21%) of rac-(3S,5S,6S,8S)-1-benzyl-8-benzyloxy-3,6-difluoro-1-azaspiro[4.5]decan. 1H NMR (400 MHz, DMSO-d6): δ 7.11-7.41 (m, 10 H), 4.98 (d, J = 56.0 Hz, 1 H), 4.79 (d, J = 52.0 Hz, 1 H), 4.48 (dd, J = 48.0, 12.0 Hz, 2 H), 3.70-4.18 (m, 2 H), 3.60 (s, 1 H), 2.91-3.02 (m, 2H), 2.42-2.47 (m, 2H), 1.88-2.09 (m, 3H), 1.47-1.70 (m, 2H), 1.14-1.18 (m, 1 H).

Step 5: rac-(3S,5S,6S,8S)-1-benzyl-3,6-difluoro-1-azaspiro[4.5]decan-8-ol

To a solution of rac-(3S,5S,6S,8S)-1-benzyl-8-benzyloxy-3,6-difluoro-1-azaspiro[4.5]decan (3.82 g, 10.28 mmol) in acetonitrile (39 mL) equally partitioned in three 30 mL microwave vials (Anton Paar apparatus) was added a suspension from equally partitioned sodium iodide (7.70 g, 51.37 mmol, 5 equiv.) and trimethylsilyl chloride (6.6 mL, 51.64 mmol, 5 equiv.) in acetonitrile (15 mL). The 3 mixture were placed in the microwave apparatus and heated to 120°C under microwave irradiation (MW) for 30 minutes. The reaction mixtures were combined and concentrated not to complete dryness under reduced pressure, taken-up into ethyl acetate (100 mL), washed with a saturated Na_2CO_3 aqueous solution then with a
2N aqueous sodium thiosulfate solution (100 mL). The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with a gradient of 0 to 10% ethyl acetate in dichloromethane to give 1.94 g (67%) of rac-(3S,5S,6S,8S)-1-benzyl-3,6-difluoro-1-azaspiro[4.5]decan-8-ol as an off-white solid. ¹H NMR (400 MHz, DMSO-d6): d 7.16-7.38 (m, 5 H), 5.09 (dt, J = 55, 5 Hz, 1 H), 4.60 (dt, J = 49, 3Hz, 1 H), 4.19 (d, J = 8 Hz, 1 H), 4.17 (s, 1 H), 3.82 (m, 1 H), 3.52 (d, J = 14 Hz, 1 H), 2.70-2.92 (m, 2 H), 2.31 (td, J = 13, 4 Hz, 1 H), 2.15 (m, 1 H), 1.82-2.10 (m, 3 H), 1.77 (m, 1 H), 1.57 (tt, J = 14, 3 Hz, 1 H), 1.20 (m, 1 H).

Step 6: rac-(3S,5S,6S,8S)-3,6-difluoro-1-azaspiro[4.5]decan-8-ol
A solution of rac-(3S,5S,6S,8S)-1-benzyl-8-benzyloxy-3,6-difluoro-1-azaspiro[4.5]decan (1.92 g, 6.82 mmol) in ethanol (250 mL) is hydrogenated at 60°C under 30 bars of hydrogen with a H-Cube Pro apparatus (Thales) using a 10% Pd/C cartridge (140 mg) and a 1 mL/minute flowrate. The solution is concentrated under reduced pressure to give 1.3 g (99%) of rac-(3S,5S,6S,8S)-3,6-difluoro-1-azaspiro[4.5]decan-8-ol. MS (ESI): mass calcd. for C₉H₁₅F₂NO, 191.1; m/z found, 192.1 [M+H]+. ¹H NMR (400 MHz, DMSO-d6): d 5.19 (d, J = 52.0 Hz, 1 H), 4.78 (br.s., 1H), 4.52 (ddd, J = 47.2, 13.2, 4.4 Hz, 1H), 3.49-3.53 (m, 1H), 3.01-3.15 (m, 2H), 1.99-2.07 (m, 3H), 1.48-1.69 (m, 4H), 1.13-1.19 (m, 1H).

To a solution of rac-(3S,5S,6S,8S)-3,6-difluoro-1-azaspiro[4.5]decan-8-ol (900 mg, 4.71 mmol) and 6-chloro-5-fluoro-2-(4-methoxybenzyl)-3,3-dimethylisoindolin-1-one (1.7 g, 5.09 mmol, 1.08 equiv.) in N,N-dimethylformamide DMF (25 mL) was added over 10 minutes a 1M solution of potassium tert-butoxide in tetrahydrofuran THF (5.4 mL, 5.40 mmol, 1.1 equiv.). The reaction mixture was stirred for 20 minutes at room temperature then poured onto a non-saturated KH₂PO₄ aqueous solution and extracted with ethyl acetate (150 mL). The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with a
gradient of 50 to 100% ethyl acetate in heptane to give 1.93 g (81%) of 6-chloro-2-[(4-methoxyphenyl)methyl]-3,3-dimethyl-5-[[rac-(3R,5R,6R,8R)-3,6-difluoro-1-azaspiro[4.5]decan-8-yl]oxy]isoindolin-1-one as a white foam. MS (ESI): mass calcd. for C_{27}H_{31}ClF_2N_2O_3, 504.1; m/z found, 505.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6): δ 7.69 (s, 1 H), 7.57 (s, 1 H), 7.30 (d, J = 9 Hz, 2 H), 6.87 (d, J = 9 Hz, 2 H), 5.20 (dtd, J = 56, 4, 2 Hz, 1 H), 4.50-4.76 (m, 4 H), 3.73 (s, 3 H), 3.03 (m, 2 H), 2.35 (m, 1 H), 1.65-2.15 (m, 6 H), 1.38 (s, 3 H), 1.36 (s, 3 H), 1.28 (m, 1 H).

Step 8: 6-chloro-5-[[3R,5R,6R,8R)-3,6-difluoro-1-azaspiro[4.5]decan-8-yl]oxy]-2-[(4-methoxyphenyl)methyl]-3,3-dimethyl-isoindolin-1-one

The racemic mixture of 6-chloro-2-[(4-methoxyphenyl)methyl]-3,3-dimethyl-5-[[rac-(3R,5R,6R,8R)-3,6-difluoro-1-azaspiro[4.5]decan-8-yl]oxy]isoindolin-1-one (1.9 g) was separated by chiral HPLC with a Chiralcel OD-I column 20μm (7.65 x 35cm) using heptane 70%/ ethanol 30%/ triethylamine 0.1% as mobile phase, a flowrate of 350 mL/min and a UV detector at 254 nm to give 916 mg (48%) of 6-chloro-5-[[3R,5R,6R,8R)-3,6-difluoro-1-azaspiro[4.5]decan-8-yl]oxy]-2-[(4-methoxyphenyl)methyl]-3,3-dimethyl-isoindolin-1-one as second eluting dextrogyre enantiomer. [α]_D = +15.2° (c= 0.0043, DMSO, 25°C). MS (ESI): mass calcd. for C_{27}H_{31}ClF_2N_2O_3, 504.1; m/z found, 505.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6): δ 7.69 (s, 1 H), 7.57 (s, 1 H), 7.30 (d, J = 9 Hz, 2 H), 6.87 (d, J = 9 Hz, 2 H), 5.20 (dtd, J = 56, 4, 2 Hz, 1 H), 4.50-4.76 (m, 4 H), 3.73 (s, 3 H), 3.03 (m, 2 H), 2.35 (m, 1 H), 1.65-2.15 (m, 6 H), 1.38 (s, 3 H), 1.36 (s, 3 H), 1.28 (m, 1 H).


A solution of 6-chloro-5-[[3R,5R,6R,8R)-3,6-difluoro-1-azaspiro[4.5]decan-8-yl]oxy]-2-[(4-methoxyphenyl)methyl]-3,3-dimethyl-isoindolin-1-one (915 mg, 1.81 mmol) and anisole (4 ml, 36.62 mmol) in trifluoroacetic acid (20 mL) was heated to 140°C for 45 minutes under microwave irradiation (Anton Paar apparatus). The reaction mixture was poured onto
saturated Na₂CO₃ aqueous solution (200 mL) and extracted with ethyl acetate (200 mL). The organic layer was separated, washed with 1N aqueous sodium hydroxide solution (100 mL), dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with ethyl acetate to give 622 mg (89%) of 6-chloro-5-[[3R,5R,6R,8R)-3,6-difluoro-1-azaspiro[4.5]decan-8-yl]oxy]-3,3-dimethyl-isoinolin-1-one as a white foam. MS (ESI): mass calcd. for C₁₉H₂₃ClF₂N₂O₂, 384.1; m/z found, 385.2 [M+H]+. 'H NMR (400 MHz, DMSO-d6): δ 8.54 (s, 1 H), 7.55 (s, 1 H), 7.50 (s, 1 H), 5.19 (dtd, J = 56, 4, 2 Hz, 1 H), 4.52-4.74 (m, 2 H), 2.82-3.13 (m, 2 H), 2.34 (m, 1 H), 1.63-2.16 (m, 6 H), 1.45 (s, 3 H), 1.44 (s, 3 H), 1.29 (m, 1 H).